RE
TGTX icon

RBC Europe’s TG Therapeutics TGTX Stock Holding History

RBC Europe’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-850
Closed -$7.35K – 1080
2019
Q2 		$7.35K Hold
850
– – ﹤0.01% 865
2019
Q1 		$6.83K Hold
850
– – ﹤0.01% 891
2018
Q4 		$3.48K Hold
850
– – ﹤0.01% 953
2018
Q3 		$4.76K Hold
850
– – ﹤0.01% 969
2018
Q2 		$11.2K Hold
850
– – ﹤0.01% 832
2018
Q1 		$12.1K Hold
850
– – ﹤0.01% 792
2017
Q4 		$6.97K Hold
850
– – ﹤0.01% 900
2017
Q3 		$10.1K Buy
+850
New +$9.68K ﹤0.01% 832

Other funds holding TGTX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RBC Europe's TGTX Position: Q3 2019 in Review

RBC Europe sold out of TG Therapeutics (TGTX) in Q3 2019, closing a stake of 850 shares — an estimated $7.35K sold.

RBC Europe first reported a position in TGTX in Q3 2017 and held it in 8 quarters. The position peaked at $12.1K in Q1 2018. 115 funds tracked by Wall St. Rank hold TGTX as of Q3 2019.

  • RBC Europe reported no remaining TG Therapeutics position as of Q3 2019 after selling out during the quarter.
  • RBC Europe sold 850 TG Therapeutics shares in Q3 2019, an estimated $7.35K.
  • RBC Europe first reported a position in TG Therapeutics in Q3 2017 and held it in 8 quarters.
  • RBC Europe's TG Therapeutics position peaked at $12.1K in Q1 2018.
  • 115 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2019.

Based on RBC Europe's 13F filing for Q3 2019, filed 9 Nov 2023.